Clinical trial
New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a…
NCT00035269 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00035269 |
|---|---|
| Title | New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia) |
| Official title | Linezolid in the Treatment of Penicillin-Resistant Streptococcus Pneumoniae Pneumonia: An Open-Label, Non-Comparator Study |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pneumonia, Pneumococcal, Community Acquired Infections, Gram-positive Bacterial Infections |
| Intervention type | Drug |
| Interventions | Antibiotic |
| Enrollment | 230 |
| Start date | Dec 1, 2001 |
| Completion | May 1, 2003 |
| First posted | May 3, 2002 |
| Last update posted | Apr 26, 2011 |
| Countries | Slovakia, Spain, Taiwan, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: